Replimune Group, Inc. (NASDAQ:REPL) Receives Consensus Rating of "Hold" from Brokerages

Key Points

• Replimune Group, Inc. has received a consensus rating of "Hold" from twelve brokerages, with one sell rating, seven hold ratings, three buy ratings, and one strong buy rating.
• The average 12-month price target for Replimune's stock is $7.67, reflecting significant downgrades from multiple analysts, including Jefferies reducing their target from $31.00 to $6.00.
• Recent insider trading activity includes CEO Sushil Patel selling 25,105 shares at an average price of $8.06, leading to a 6.81% decrease in his ownership stake.

Shares of Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) have been assigned a consensus recommendation of "Hold" from the twelve brokerages that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, three have given a buy rating and one has issued a strong buy rating on the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $7.6667.

A number of analysts have recently issued reports on the stock. Piper Sandler lowered shares of Replimune Group from an "overweight" rating to a "neutral" rating and set a $3.00 target price for the company. in a research note on Tuesday, July 22nd. HC Wainwright lowered shares of Replimune Group from a "buy" rating to a "neutral" rating in a research note on Wednesday, July 23rd. Jefferies Financial Group lowered their target price on shares of Replimune Group from $31.00 to $6.00 and set a "buy" rating for the company in a research note on Tuesday, July 22nd. Leerink Partners reissued a "market perform" rating and set a $3.00 target price (down from $21.00) on shares of Replimune Group in a research note on Tuesday, July 22nd. Finally, Leerink Partnrs lowered shares of Replimune Group from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, July 22nd.

Insiders Place Their Bets

In other Replimune Group news, CEO Sushil Patel sold 25,105 shares of the business's stock in a transaction dated Tuesday, May 20th. The shares were sold at an average price of $8.06, for a total value of $202,346.30. Following the completion of the transaction, the chief executive officer directly owned 343,576 shares in the company, valued at approximately $2,769,222.56. The trade was a 6.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Christopher Sarchi sold 3,749 shares of the business's stock in a transaction dated Tuesday, May 20th. The stock was sold at an average price of $8.05, for a total transaction of $30,179.45. Following the completion of the transaction, the insider owned 128,296 shares of the company's stock, valued at $1,032,782.80. This represents a 2.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 74,907 shares of company stock valued at $603,655 in the last three months. 5.20% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Replimune Group

Several hedge funds have recently modified their holdings of the stock. Price T Rowe Associates Inc. MD increased its holdings in shares of Replimune Group by 11.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 10,962,883 shares of the company's stock valued at $132,761,000 after acquiring an additional 1,083,633 shares in the last quarter. Redmile Group LLC increased its holdings in shares of Replimune Group by 2.6% during the fourth quarter. Redmile Group LLC now owns 4,905,527 shares of the company's stock valued at $59,406,000 after acquiring an additional 124,344 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Replimune Group by 6.6% during the first quarter. Vanguard Group Inc. now owns 3,833,033 shares of the company's stock valued at $37,372,000 after acquiring an additional 237,185 shares in the last quarter. Tang Capital Management LLC increased its holdings in shares of Replimune Group by 125.0% during the fourth quarter. Tang Capital Management LLC now owns 2,700,000 shares of the company's stock valued at $32,697,000 after acquiring an additional 1,500,000 shares in the last quarter. Finally, RTW Investments LP increased its holdings in shares of Replimune Group by 82.1% during the fourth quarter. RTW Investments LP now owns 2,065,010 shares of the company's stock valued at $25,007,000 after acquiring an additional 931,223 shares in the last quarter. Institutional investors and hedge funds own 92.53% of the company's stock.

Replimune Group Trading Down 3.0%

REPL stock opened at $5.10 on Thursday. The stock has a market capitalization of $397.72 million, a price-to-earnings ratio of -1.57 and a beta of 0.67. Replimune Group has a twelve month low of $2.68 and a twelve month high of $17.00. The company has a quick ratio of 7.95, a current ratio of 6.94 and a debt-to-equity ratio of 0.21. The firm's fifty day simple moving average is $8.42 and its two-hundred day simple moving average is $9.72.

Replimune Group (NASDAQ:REPL - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.83) by ($0.12). As a group, analysts anticipate that Replimune Group will post -2.97 earnings per share for the current year.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.